AnAPN1 Vaccine

AnAPN1 Vaccine

The Anopheline mosquito midgut-specific alanyl aminopeptidase N (AnAPN1) is a highly conserved luminal midgut surface glycoprotein that is involved in bloodmeal digestion.  We have recently shown that antibodies elicited against this antigen can significantly block parasite development in the mosquito and the subsequent cascade of secondary infections once the mosquito takes a bloodmeal from another individual.  This type of transmission-blocking vaccine (TBV) is termed "mosquito-based", since it differs from other malaria TBVs which are targeting parasite surface antigens. It has been estimated that more than 1-2 million individuals succumb to Malaria every year, a majority of whom are children under the age of five.  Plasmodium parasites, the causative agent of malaria, are transmitted to a vertebrate host by the infective bite of an Anopheles mosquito.  Malaria transmission-blocking vaccines (TBVs) are a critical tool for disease elimination. TBVs prevent completion of the developmental lifecycle of malarial parasites within the mosquito vector, effectively blocking subsequent infections. The mosquito midgut protein Anopheline alanyl aminopeptidase N (AnAPN1) is the leading, mosquito-based TBV antigen to date.
[Pictured: Anopheles gambiae membrane feeding on infected blood]

Contact Us

Learn more about the research in the Dinglasan Laboratory.

Join us on the mission!

Latest News

Stay Up To Date With Our Latest News. Learn About New PUBLICATIONS, Treatments, Vaccines, Our Lab & Much More!
First in human clinical trials of the AnAPN1 malaria transmission-blocking vaccine

Former director of the PATH Malaria Vaccine Initiative, Christian Loucq, M.D., says it is exciting to see Dinglasan's concept moving toward a clinical trial. "There are very interesting issues to be addressed in this project which span the technical, immunological, strategic, regulatory and behavioral," says Dr. Loucq, who also formerly directed the International Vaccine Institute. "A transmission-blocking vaccine would be the most elegant solution to the problem of malaria."

Clustered rapid induction of apoptosis limits ZIKV and DENV-2 proliferation in the midguts of Aedes aegypti

Jasmine's 1st first-author paper (Yay Jasmine!) that dissects very early innate immune defense mechanisms of mosquito vectors following infection with flaviviruses.

UF Professor of Infectious Diseases, Dr. Rhoel Dinglasan, discusses the new saliva COVID tests